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Abstract
Background: There is inadequate evidence to determine whether there is an effect of alcohol 
consumption on lung cancer risk. We conducted a pooled analysis of data from the International 
Lung Cancer Consortium and the SYNERGY study to investigate this possible association by type 
of beverage with adjustment for other potential confounders.
Methods: Twenty one case-control studies and one cohort study with alcohol-intake data 
obtained from questionnaires were included in this pooled analysis (19,149 cases and 362,340 
controls). Adjusted odds ratios (OR) or hazard ratios (HR) with corresponding 95% confidence 
intervals (CI) were estimated for each measure of alcohol consumption. Effect estimates were 
combined using random or fixed-effects models where appropriate. Associations were examined 
for overall lung cancer and by histological type.
Results: We observed an inverse association between overall risk of lung cancer and 
consumption of alcoholic beverages compared to non-drinkers, but the association was not 
monotonic. The lowest risk was observed for persons who consumed 10–19.9 g/day ethanol (OR 
vs. non-drinkers = 0.78; 95% CI: 0.67, 0.91), where 1 drink is approximately 12–15 g. This J-
shaped association was most prominent for squamous cell carcinoma (SCC). The association with 
all lung cancer varied little by type of alcoholic beverage, but there were notable differences for 
SCC. We observed an association with beer intake (OR for ≥20 g/day vs nondrinker = 1.42; 95% 
CI: 1.06, 1.90).
Conclusions: Whether the non-monotonic associations we observed or the positive association 
between beer drinking and squamous cell carcinoma reflect real effects await future analyses and 
insights about possible biological mechanisms.
Keywords
Alcohol; Lung cancer; Pooled analysis
1. Introduction
Lung cancer remains the leading cause of cancer-related mortality globally [1]. Tobacco 
consumption is unquestionably the predominant risk factor for the disease with 80–90% of 
cases occurring among former or current smokers [2,3]. As larger cohorts and consortia 
efforts mature, the ability to estimate less prominent risk factors in large datasets emerge. A 
multitude of risk additional factors for lung cancer have been identified [4–7]. One 
additional risk factor of potential interest is the intake of alcohol and the interaction between 
alcohol and tobacco consumption [8]. Alcohol has shown to be inconsistently associated 
with lung cancer risk in previous meta-analyses of case-control and cohort studies, with 
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several previous studies reporting an increased risk for high doses [9,10] in a non-linear 
fashion [11], while others reporting that the associations are dependent upon beverage type 
with increased risks for liquor and beer and an inverse relationship with consumption of red 
wine [12]. While meaningful associations have been observed across different studies 
designs, many of these studies have been unable to reach conclusive associations due to the 
potential for residual confounding or inadequate statistical power. Systematic reviews by the 
International Agency for Research on Cancer and the World Cancer Research Fund/
American Institute for Cancer Research stated that there is inadequate evidence to support 
an association between alcohol consumption and lung cancer risk [13]. An examination of 
the associations between alcohol and lung cancer by beverage type, histology groups as well 
as the interaction with tobacco consumption within a standard analytical framework 
confounders is warranted.
To address these questions we pooled data from twenty one studies participating in the 
International Lung Cancer Consortium (ILCCO) and the SYNERGY consortium and 
standardized exposure and covariate data across studies.
2. Methods
2.1. Data collection
ILCCO and SYNERGY study inclusion and details have been previously published [14] and 
are available on the web portals (http://ilcco.iarc.fr) (http://synergy.iarc.fr). Twenty two 
participating studies contributed data ascertaining alcohol and agreed to participate in this 
pooled analysis (Table 1 & Supplementary Table 1). Eleven studies were conducted in North 
America, eight studies in Europe and three in Asia. There were twenty one case-control 
studies, of which ten were population-based, eight hospital-based and three studies with 
mixed (hospital and population) controls (Supplementary Table 2). There was one large 
population-based cohort study, the European Prospective Investigation into Cancer (EPIC) 
study [15]. The control groups in all case-control studies were, either individually or, 
frequency-matched with cases on age and sex. The analyses included in this manuscript 
examine the associations between alcohol consumption and lung cancer risk across all 
tobacco consumption groups. Given the importantly different baseline risk profile among 
never smokers, we have presented detailed analyses of alcohol consumption and lung cancer 
risk restricted to never smokers in a separate publication [16]. Written informed consents 
were obtained from all study subjects, and ethics review boards at each study center 
approved the studies.
The data submitted from all studies were checked for inadmissible values, aberrant 
distributions, inconsistencies and missing values. Queries were sent to the investigators to 
resolve all discrepancies and possible errors. A total of 19,149 cases and 362,340 controls 
were available for the present investigation.
Alcohol intake was collected in each study using questionnaire data. The entry formats and 
questions varied across studies. A full description of the different types of questions asked is 
shown in Supplementary Table 3. Wherever possible, we converted the question responses 
into standardized drink units based on the quantities inquired by the questionnaires. These 
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were converted into grams of alcohol per day based on data from the International Agency 
for Research on Cancer (http://cancer-code-europe.iarc.fr/) for alcoholic beverages. The 
duration of alcohol consumption was calculated wherever possible through the use of 
duration questions or questions aimed at drinking during particular periods or decades of the 
life. From the available measures, drink-years (drinks/day*years of drinking) and average 
grams of ethanol per day consumed during adulthood for alcohol intake overall and for each 
beverage type were calculated. Regular drinkers were defined as those consuming at least 
one alcoholic drink per week. We used non-drinkers as the reference group for our analyses. 
This choice was made to enable comparison with other large pooled [9] and meta-analyses 
[12,17] of alcohol intake and, in particular, to estimate the effects of low volumes of habitual 
consumption. In the beverage type analyses, non-drinkers that did not consume alcohol of 
any type were used as the reference group.
2.2. Statistical analyses
The frequency distribution of demographic variables and putative risk factors for lung 
cancer, including age, sex, ethnicity, and smoking, were examined among all cases and 
controls. The ethnicity of the subjects were categorized according to the National Institutes 
of Health (NIH) definition as non-Hispanic Whites, Blacks or African Americans, Hispanic 
or Latinos, Asians, Native Hawaiians or other Pacific islanders, American Indians or others. 
Former smokers were defined as smokers who quit smoking at least two years before the 
interview or diagnosis. Cumulative tobacco consumption was calculated as the product of 
smoking duration and intensity throughout the life-course standardized across studies and 
expressed as pack-years.
For the case-control studies, unconditional logistic regression was used to estimate odds 
ratios (OR) and their associated confidence intervals (95% CI), adjusted for age, sex, 
cumulative tobacco smoking (in pack-years), and country or study center (when the study 
was conducted in multiple countries or centers) for the effects of each type and measure of 
alcohol consumption. For the cohort study, we used Cox proportional hazards regression 
(with time since enrollment as the time scale) to estimate hazard ratios (HR) and their 
associated 95% CIs adjusted for the same factors as case-control studies. Follow-up time at 
risk was calculated as the time between study enrollment and lung-cancer diagnosis (for 
cases) or the last known date of query (for non-cases) from the cancer registry. We estimated 
pooled effects across studies employing the inverse variance method and using fixed and 
random-effects models to account for variability between study populations. We conducted 
sensitivity analyses with and without the cohort study to examine for excess influence on the 
results to the size of the population.
We conducted a stratified analysis by histological subtypes to examine for potential 
differential effects with models conducted in each study and then pooled using random 
effects. Of great interest were potential synergistic interactions between alcohol and tobacco 
consumption. In order to examine the interaction between alcohol and tobacco consumption, 
we pooled data into a single population and employed a fixed-effects analysis adjusted for 
study. We then examined a departure from an additive scale by comparing observed effect 
estimates in combined tobacco and alcohol exposure groups. We also conducted a test of a 
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multiplicative interaction between pack-years of smoking and grams of ethanol per day. In 
order to examine graded risk with the lower risk for both smoking and alcohol consumption 
categories, we used the 0 < 20 g/day group as the reference group as nondrinkers had an 
increased risk compared to light drinkers. We also analyzed ethanol consumption as a 
continuous variable. Non-linear effects were examined through the use of restricted cubic 
splines in a combined dataset. A 5-knot term was used, as this best fit the data based on the 
log-likelihood.
As several of the studies included in the pooled analysis contained lifetime occupational 
data, we evaluated whether the effect estimates we observed were potentially confounded by 
ever employment in occupations and industries known to present an excess risk of lung 
cancer (List A) [18] or occupations and industries suspected to present an excess risk of lung 
cancer (List B) [19]. We also evaluated potential confounding due to the presence of a 
previous lung disease. Several of the studies collected self-reported previously diagnosed 
tuberculosis at the time of interview. As the presence of a lung disease may have impacted 
the amount of regular alcohol consummation, we compared the average lifetime alcohol 
consumption across those with and without a history of tuberculosis.
Heterogeneity was evaluated for each of the summary estimates based on a test of the 
Cochrane Q statistic as well as the I2 statistic [20]. Where there was evidence of 
heterogeneity across studies, we evaluated the source of heterogeneity by meta-regression 
using continent (North America, Europe, Asia, etc.), control type (population, hospital, 
mixed), prevalence of ever smoking among controls (continuous), % male of the population, 
% Caucasian and median year of the study period (continuous) as predictors. Statistical 




Among regular drinkers the average number of grams of ethanol per day consumed from all 
types of alcoholic drinks was 24 g. This corresponds to 2 drinks per days. We observed a 
slight inverse association for low doses of alcohol in the range of less than 20 g of alcohol 
per day (Table 2). This effect persisted across all histologic subtypes including 
adenocarcinoma and squamous cell carcinoma. No inverse associations or increased risks 
were observed for high levels of overall alcohol consumption on lung cancer risk. The non-
linear effects of ethanol per day on lung cancer risk can be seen in Fig. 1. A clear dip in the 
odds of being a case is seen at low to moderate levels of drinking. As expected we observed 
heterogeneity in the main effects of alcohol on lung cancer risk (p < 0.001) due to 
differences across populations. Study-specific results are presented across alcohol 
consumption categories with corresponding I2 and p-values for heterogeneity are presented 
in Supplementary Fig. 1. When we examined the main effects of alcohol consumption in a 
meta-regression using continent, control type, prevalence of ever smoking among controls 
(continuous) and median year of the study period (continuous) as predictors, no single study 
characteristic appeared to drive the heterogeneity.
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When comparing the overall effect estimates with the EPIC cohort study included or 
removed from analyses, the pooled effect estimates did not differ materially. For example, 
the effects among the >0–4.9 g/day group compared to non-drinkers including the cohort 
study OR = 0.79, 95%CI = 0.72–87 and without the cohort study OR = 0.79, 95%CI = 0.70–
0.89. For this reason the cohort was retained in the combined results.
3.2. Alcoholic beverage type
When examining the effects of consuming different alcoholic beverage types adjusted for 
other types of beverages, an inverse association between drinking and lung cancer risk was 
observed for wine and liquor consumption, but not for beer consumption, where risk 
estimates were elevated for higher categories of grams of ethanol from beer compared with 
non-drinkers (OR = 1.09, 95% CI = 0.94–1.27, for ≥20 g/day) (Table 3). Increases in risk 
associated with beer consumption were observed among subgroup analyses of squamous cell 
carcinoma (OR = 1.42, 95% CI = 1.06–1.90, for ≥20 g/day). In accordance with the results 
in the overall analyses, a decrease in risk was also observed for wine consumption with the 
strongest effects observed for squamous cell carcinoma (OR = 0.71, 95% CI = 0.53–0.94, 
for 10–19.9 g/day).
3.3. Interaction with smoking
We divided the population into groups according to alcohol consumption (non-drinkers (0 g/
day), 0- <20 g/day and ≥20 g/day) and tobacco consumption (0 pack-years, 0- <10 pack-
years, >10 pack-years). An interaction analysis between the smoking and drinking categories 
suggested, as expected that lung cancer risk was associated with higher levels of tobacco 
consumption. An interaction was observed for those in the highest alcohol and tobacco 
consumption groups, where the effect estimate deviated from that expected on the additive 
scale (OR = 11.23, 95% CI = 10.29–12.26, >20 g/day, >10 pack-years). The test for 
multiplicative interaction between alcohol consumption and smoking intensity was also 
significant (P < .001) (Table 4).
3.4. Investigation of potential confounding
When we evaluated whether the effect estimates we observed were potentially confounded 
by ever employment in occupations and industries known to present an excess risk of lung 
cancer, we did not observe any notable differences between ORs with and without 
adjustment for List A or List B (Supplementary Table 4). When we examined the presence 
of reporting a history of tuberculosis at diagnosis or interview we saw no appreciable 
difference in the proportions between never drinkers and drinkers (Supplementary Table 5).
4. Discussion
4.1. Summary of effects
We observed no increased risk of lung cancer associated with high intakes of total alcohol 
consumption alcoholic beverages. Similar null effects were observed across lung cancer 
histologic subtypes. However, specifically for higher level of beer consumption, we 
observed increased risks of lung squamous cell carcinoma. On the other hand, a slight 
inverse association (i.e. protective effect) was observed for low to moderate alcohol 
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consumption compared to non-drinkers. We also observed evidence of increased risks of 
adenocarcinoma and overall lung cancer for the highest categories of beer consumption, as 
well as evidence of increased risk of squamous cell carcinoma for the highest level of liquor 
consumption. In contrast, we did not observe any evidence of an increased in overall or sub-
type specific risk with higher levels of wine consumption. Our study findings are more 
robust than previous analyses due to the large sample size from 21 pooled studies as well as 
standardized variable characterization and adjustment across the studies.
Our results are in line with previous meta-analyses [12,17] and analyses of large datasets [9] 
that suggested a J-shaped association for overall consumption of grams of alcohol per day. 
Freudenheim et al. (2005) observed an inverse association (OR = 0.81, 95% CI = 0.68–0.97 
(5- <15 g/day vs 0 g/day) among women, OR = 0.86, 95% CI = 0.76–1.28 (> 0− <5 g/day vs 
0 g/day among men)) when compared to never drinkers in a pooled analyses of multiple 
prospective cohort studies [9]. This suggests a level of consistency between our study and 
the other largest studies done to date, which includes a large proportion of the published data 
available on this association.
4.2. Inverse associations among light/low levels of drinking
Our beverage type-specific results are also consistent with previous analyses of large 
datasets [9]. Freudenheim et al. also observed an inverse association for 1–2 glasses of wine 
per day (OR = 0.66, 95% CI = 0.51–0.87 (5- <15 g/day vs 0 g/day) among men, OR = 0.78, 
95% CI = 0.52–1.07 (5- <15 g/day vs 0 g/day) among women) and increased risk observed 
with beer drinking (OR = 1.88, 95% CI = 1.45–2.42 (5- <15 g/day vs 0 g/day) among 
women) and liquor consumption (OR = 1.34, 95% CI = 1.09–1.66 (5- <15 g/day) among 
women). The authors concluded that the associations at higher levels of consumption may be 
in part explained by residual confounding from tobacco, lung diseases and other 
confounders. A meta-analysis of case-control and cohort studies conducted by Chao also 
suggested an inverse association for wine drinking 0.79 (0.65–0.95) and an increased risk 
associated with the highest category of beer drinking at 1.23 (1.06–1.41) [12] when 
comparing highest to lowest intakes in the studies. In consideration of potential residual 
confounding due to tobacco smoking, it is relevant to examine the effects of alcohol 
consumption among never smokers. In a companion analyses, we examined the effects of 
alcohol in the same set of studies included here, focused solely on never smokers [16]. We 
observed similar small inverse associations with moderate drinkers.
Before considering a possible causal interpretation of the potential inverse association with 
low alcohol consumption, there are at least two alternative explanations. First, there may be 
confounding by a correlate of low alcohol consumption, that might be characterized by the 
phrase “balanced-lifestyle” and that might entail habits such as low smoking percentages, 
increased cruciferous vegetable intake [21], citrus fruit intake [22], garlic [23], tea 
consumption [24] and/or elevated levels of recreational physical activity [25,26]. While 
these may individually have small protective effects, the collective presence of these factors 
may entail a larger effect which could confound the wine-cancer association. In the 
University of North Carolina Alumni Heart Study, the lowest prevalence of cigarette 
smoking was observed among drinkers who preferred wine compared to liquor and beer, 
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respectively [27]. The second possible explanation would be that those who are abstaining 
from drinking are not doing so by choice, but by necessity. For example, an exposure such as 
a previous lung disease or family history has altered alcohol and or tobacco consumption. 
This imbalanced exposure profile would artificially place the reference group at a higher risk 
than those in the moderate consumption categories. However, further adjusting history of 
tuberculosis did not affect our results.
A causal interpretation is compatible with the finding that there are anti-carcinogenic 
properties in alcohol beverages. In particular, poly-phenolic compounds including flavonoids 
in red wine have well characterized anti-carcinogenic properties [28]. Evidence from other 
population studies suggests that flavonoids, such as quercetin intake may reduce the risk of 
lung cancer through anti-oxidative pathways [29–31]. Additional ingredients of alcoholic 
beverages, such as xanthohumol and resveratrol have also been shown to have cancer 
chemopreventive properties [32,33].
Further investigation and future analyses are required to support and justify the findings of 
this study. Additional analytical approaches such as Mendelian Randomization [34] to 
reduce differential measurement error and instrumental variable analyses [35] to control for 
unmeasured confounding where consumption patterns vary widely enough to act as strong 
instruments may provide additional support to our results through a triangulation [36] of 
approaches. From a biological pathway perspective additional mouse model studies 
examining the hypothesized carcinogenic components of alcohol and tobacco exposure may 
also provide additional triangulation support [36] of the interactive effects we observed.
4.3. Increased risk with high levels of beer consumption among squamous cell 
carcinoma
We observed a greater relative risk associated with high levels of beer consumption for 
squamous cell carcinoma than for adenocarcinoma. As squamous cell carcinomas are more 
frequently observed among heavy smokers, this association might further reflect residual 
confounding from tobacco in the use, particularly when assessing alcohol consumption. This 
follows the previously suggested contention that residual confounding from smoking is 
likely to be stronger in the highest consumption categories, due to an excess of extremely 
heavy smokers among these cases [10].
4.4. Interaction with smoking
We observed a positive interaction between high pack-years of smoking and elevated levels 
of drinking. This may reflect some type of biological interaction of the combination of the 
two exposures or it may also reflect a different exposure profile across drinking categories 
where those at higher levels of both alcohol and tobacco consumption may be exposed to 
other factors, such as second-hand smoke from time spent in bars.
From a biological perspective, alcohol may interact with and enhance the carcinogenicity of 
tobacco smoke by inducing the activity of cytochrome P-450 enzymes, which could activate 
the harmful substances, such as ethanol, present in alcoholic beverages [8,37]. Our study is 
in agreement with the vast majority of the literature where synergistic effects among 
categories of high levels of both alcohol and tobacco consumption have been observed [38]. 
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Both alcohol and nicotine are known to impact the same mesolimbic dopamine system [39]. 
This mediates the rewarding and reinforcing properties of both substances and may lead 
heavy drinkers to smoke more and vice versa.
4.5. Limitations
As 21 of 22 studies included in this analyses were case-control studies, the limitations of 
assessing association within the case-control design are a limitation of this larger pooled 
analysis. We were able to compare the associations observed within the single cohort study 
included in this analyses and we observed relatively similar findings, however, the impact of 
recall bias and differential misclassification on these associations cannot be ruled out. 
Alcohol intake was determined by questionnaires inquiring about lifetime intake. As with 
other food frequency questionnaires, the measurements are influenced by notable 
misclassification due to various factors influencing responses. The level of detail from 
questionnaires used to estimate the average intake of ethanol weighted over adulthood varied 
across studies. This variation may have contributed to the heterogeneity observed across 
study-specific estimates. Some questionnaires asked a simple question about average 
number of alcoholic drinks per day over adulthood, while others asked specific questions 
about the type of drink and consumption over small windows of time over the life-course. 
This may have introduced varying degrees of misclassification into our measures, therefore 
complicating an estimation of the potential effect on the relationship between our estimates 
and the true risk estimates associated with exposure. However, we did attempt to minimize 
any effect on the result from such misclassification through standardizing measurements 
across studies, removing aberrant measurements, and controlling for common confounders 
between the studies.
In order to determine the causality of this association, controlling confounding due to 
tobacco is paramount. Although we have used pack-years of smoking for adjustment, which 
is a relatively detailed combined construct of cumulative duration and intensity, it is possible 
that some degree of residual confounding remains. Furthermore, despite a large number of 
studies we were unable to investigate the differential effects of the alcohol tobacco 
interaction across histology groups due to a lack of statistical power.
4.6. Strengths
This is one the largest datasets queried to date to assess the question of whether alcohol 
consumption and the varying types of alcohol drinks that are consumed is associated with 
lung cancer risk. A previous meta-analysis of alcohol consumption and lung cancer cited an 
inability to examine effect across histology groups12. This analysis was able to examine 
these associations by drink across histologic sub-types with adequate precision. The 
generalizability of this investigation is strengthened of this particular investigation is the 
existence of data from multiple studies from three continents. This analysis is also 
strengthened by the ability to examine the potential for confounding due to the history of 
tuberculosis and occupational exposures in a subgroup of the included studies. Furthermore, 
detailed data on smoking also allowed for a more standardized adjustment than in previous 
analyses.
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Although we cannot advocate for alcohol consumption to reduce the risk of lung cancer as 
alcohol has multiple known adverse effects, our results replicate a slight inverse association 
with wine consumption at low to moderate levels warrant further research into the 
mechanisms involved. This result is also compatible with the explanation based on balanced 
lifestyle typically seen among low to moderate drinker.
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Refer to Web version on PubMed Central for supplementary material.
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Odds of lung cancer associated with grams of alcohol consumption in the combined 
International Lung Cancer Consortium and Synergy Consortium Study population.
*See PNG file attachment
Figure represent the odds of being a case compared to a control across the distribution of 
grams of ethanol consumed in the study populations estimated from the combined 
population. The blue line represents the point estimate and the grey shaded area represents a 
95% confidence interval. Models were adjusted for age, sex, pack-years, education, ethnicity 
and center/country where appropriate.
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Table 1
Population characteristics for combined International Lung Cancer Consortium and Synergy Consortium 
Study population (N cases = 16,808) (N controls =21,258). The European Prospective Investigation into 
Cancer and Nutrition (EPIC) study characteristics are presented in Supplementary Table 1.
Controls Cases
n (%) n (%)
Sex
 Female 7,243 34.1 5,774 34.4
 Male 14,015 65.9 11,034 65.6
Age groups
 < 50 3,384 15.9 1,987 11.8
 50 < 55 2,663 12.5 2,056 12.2
 55 < 60 3,466 16.3 2,853 17.0
 60 < 65 3,427 16.1 2,731 16.2
 65 < 70 3,672 17.3 2,961 17.6
 70 + 4,646 21.9 4,220 25.1
Age years (mean ± sd) 60.3 (11.1) 61.7 (10.5)
Education level
 Basic/elementary 4,708 22.1 4,637 27.6
 Up to high school graduate 7,286 34.3 6,209 36.9
 Some postsecondary and higher 5,299 24.9 2,910 17.3
 Missing or unspecified 3965 18.7 3052 18.2
Race/ethnicity
 White 15,636 73.6 13,737 81.7
 Black, African-American 1,198 5.6 721 4.3
 Asian 3,981 18.7 2,149 12.8
 Hispanic 258 1.2 101 0.6
 Other unknown 185 0.9 100 0.6
Smoking groups
 Never 7,992 37.6 2,067 12.3
 Former 7,694 36.2 5,977 35.6
 Current 5,540 26.1 8,748 52.0
 Unknown 32 0.2 16 0.1
Pack-years (mean ± sd) 18.3 (25.1) 41.6 (32.3)
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Table 2
Associations with categories of grams of alcohol consumption combined from all types of drinks in the 
combined International Lung Cancer Consortium and Synergy Consortium Study population. Effect estimates 
from random effects models across studies. (N cases = 19,149) (N controls = 362,340).
Group Number of studies n cases n controls OR1 95% CI
Overall
Non-drinkers 21 4,204 31,950 1.00 REF
0–4.9 g per day 21 3,439 124,752 0.79 0.72–0.87
5–9.9 g per day 21 2,342 66,107 0.85 0.74–0.96
10–19.9g per day 21 3,022 68,975 0.78 0.67–0.91
20–29.9 g per day 20 1,796 30,438 0.98 0.85–1.12
30–44.9g per day 20 1,639 20,334 0.92 0.82–1.04
≥45g per day 19 2,707 19,784 0.94 0.77–1.15
Adenocarcinoma
Non-drinkers 21 1,776 31912 1.00 REF
0–4.9 g per day 21 1,384 124751 0.78 0.71–0.86
5–9.9 g per day 21 870 66104 0.88 0.76–1.02
10–19.9 g per day 21 1,067 68984 0.82 0.70–0.97
20–29.9 g per day 19 561 30422 0.99 0.85–1.15
≥30g per day 18 1,189 40017 0.88 0.73–1.05
Squamous Cell Carcinoma
Non-drinkers 20 860 31,846 1.00 REF
0–4.9 g per day 20 639 124,668 0.71 0.59–0.86
5–9.9 g per day 20 531 66,080 0.78 0.64–0.95
10–19.9 g per day 20 782 68,907 0.77 0.62–0.94
20–29.9 g per day 18 510 30,345 0.96 0.79–1.18
≥30g per day 18 1,466 39,870 1.01 0.80–1.28
Small Cell Lung Cancer
Non-drinkers 14 347 3,883 1.00 REF
0–4.9 g per day 14 273 3,587 0.81 0.66–0.99
5–9.9 g per day 14 199 2,354 0.94 0.67–1.31
10–19.9 g per day 14 285 2,995 0.91 0.66–1.25
20–29.9 g per day 13 177 1,409 1.08 1.80–1.46
≥30g per day 13 448 2,813 0.91 0.66–1.25
Models adjusted for sex, age group, pack-years, education, ethnicity and center/country where appropriate.
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Table 4
Joint effects of alcohol and tobacco consumption combined in International Lung Cancer Consortium and 
Synergy Consortium Study population. Effect estimates from a fixed effects model in a single combined 
population.
Odds ratios for smoking and alcohol Categories
Drinking and smoking categories OR1 95% CI
0 < 20g Alc per day, 0 pack-years 1.00 REF
0 < 20 g Alc per day, 0 < 10 pack-years 1.31 1.16–1.48
0 < 20g Alc per day, 10+ pack-years 7.74 7.14–8.39
0 g Alc per day, 0 pack-years 1.64 1.48–1.82
0 g Alc per day, 0 < 10 pack-years 1.85 1.54–2.23
0 g Alc per day, 10+ pack-years 9.81 8.92–10.80
20 + g Alc per day, 0 pack-years 0.86 0.72–1.03
20 + g Alc per day, 0 < 10 pack-years 1.57 1.32–1.87
20 + g Alc per day, 10+ pack-years 11.23 10.29–12.26
Controlling for sex, age, pack-years, education, ethnicity and study.
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